Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

Abstract

Adalimumab demonstrated sustained maintenance of clinical remission, improvements in quality of life and reductions in hospitalization during long-term treatment for CD, with no new safety concerns identified.